Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytomegalovirus-specific cytotoxic T lymphocytes (Memorial Sloan Kettering Cancer Center)
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Cytomegalovirus-specific cytotoxic T lymphocytes (CMV CTLs) are a form of adoptive cell therapy used to treat and prevent cytomegalovirus (CMV) infections, particularly in immunocompromised patients following hematopoietic stem cell transplantation (HSCT) or solid organ transplantation. These are T cells specifically reactive to CMV antigens such as phosphoprotein pp65 or immediate early-1 (IE-1) protein. CMV CTLs can be derived from donors (including third-party donors) or expanded from granulocyte colony-stimulating factor-mobilized hematopoietic progenitor cell products. They function by recognizing and eliminating CMV-infected cells, providing long-term protection against CMV reactivation. This therapy is particularly valuable for treating refractory CMV infections that are resistant to conventional antiviral medications.
- Other names
- virus-specific cytotoxic T-lymphocytesCMV pp65-specific cytotoxic T lymphocytesCMV IE-1-specific cytotoxic T lymphocytes
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on cytomegalovirus-specific cytotoxic T lymphocytes (Memorial Sloan Kettering Cancer Center).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytomegalovirus-specific cytotoxic T lymphocytes (Memorial Sloan Kettering Cancer Center).